Shionogi & Co. has announced that effective immediately, Shionogi has regained full rights to Symproic (naldemedine) tablets 0.2 mg in the United States. As Purdue Pharma is taking significant steps to transform and diversify beyond its historical focus on opioid pain medications, Shionogi and Purdue have agreed to terminate the prior alliance for the US co-commercialization of Symproic.
Shionogi has no residual financial or other obligations to Purdue. Shionogi has begun its own sales and distribution of Symproic, and is in the process of seeking a new partner with strong commercial capabilities.
(Source: Shionogi & Co., Ltd.)